Thymidylate synthase (EC 2.1.1.45) is a key enzyme for the de novo synthesis of DNA and as such a target for anticancer drug development. There is a need to develop noninvasive methods for assessing thymidylate synthase inhibition in tumors. The aim of this study was to assess the potential of 3 ¶-deoxy-3 ¶-[
Introduction
Thymidylate synthase (EC 2.1.1.45) is a critical enzyme for DNA replication because it catalyses the de novo synthesis of thymidine monophosphate (TMP), a key nucleotide precursor for DNA synthesis. Due to its central role in DNA synthesis, thymidylate synthase remains an exploitable target for anticancer drug development. Pyrimidines, such as 5-fluorouracil (5-FU) in combination with leucovorin, a reduced folate that stabilizes the binding of 5-FU to thymidylate synthase, have been used for several decades in the treatment of gastrointestinal and other cancers (1) (2) (3) . More recently oral 5-FU prodrugs, such as capecitabine, have been developed (1, 4, 5) . In addition to these pyrimidines, inhibitors that are structural analogues of 5,10-methylenetetrahydrofolate, a cosubstrate of thymidylate synthase, generally referred to as antifolates, have been developed. These include raltitrexed, permetrexed, nolatrexed, and BGC 9331 (ZD9931; refs. 6-9). Whereas the above agents inhibit both normal tissue and tumor thymidylate synthase, new antifolates, such as BGC 638 and BGC 945, are targeted to tumors via the a-folate receptor, leading to selective inhibition of tumor thymidylate synthase (6, 10, 11) .
Quantification of thymidylate synthase inhibition in tumors currently relies on measurement of biochemical changes that accompany thymidylate synthase inhibition (2, 7) . For instance, thymidylate synthase inhibition leads to an increase in intracellular pools of the thymidylate synthase substrate dUMP and its corresponding nucleoside 2 ¶-deoxyuridine; thus, pharmacodynamic effects of thymidylate synthase inhibitors have been assessed by measuring elevation of this nucleoside in the patient's plasma (7, 8) . However, elevated plasma 2 ¶-deoxyuridine is mainly a marker of global thymidylate synthase inhibition in proliferating cells (i.e., not tumor specific). Positron emission tomography (PET) imaging of thymidylate synthase biochemistry is a strategy that may provide more specific information at the tumor site and could have important use in the development of the next generation of thymidylate synthase inhibitors.
The positron emitting radiotracer 2-[ 11 C]thymidine, a substrate for thymidine kinase 1 (TK1; cytoplasmic thymidine kinase; EC2.7.1.21 ref. 12 ), a key enzyme in salvage pathway for producing TMP (13) , has been assessed for its potential for imaging thymidylate synthase inhibition (14) . In that study, patients treated with nolatrexed and scanned 1 hour after drug administration had an increase in tumor 2-[
11 C]thymidine-related radioactivity levels that correlated with area under the plasma nolatrexed concentration versus time curve (14) . It was hypothesized that inhibition of the de novo pathway will lead to enhanced use of TMP produced via the salvage pathway and hence 2-[ 11 C]thymidine uptake. The radiotracer 2-[
11 C]thymidine is, however, not an ideal PET marker because it is rapidly metabolized in vivo (15) . In the present report, we investigated the feasibility of the more metabolically stable thymidine analogue, 3 ¶-deoxy-3 ¶-[ 18 Kingdom, 1990 ) and in full compliance with government regulations and guidelines on the welfare of animals in experimental neoplasia (19) . Tumors were selected for PET imaging studies when they reached 5 to 8 mm in diameter.
PET scanning and image analysis. Mice were scanned on a dedicated small animal PET scanner (quad-HIDAC; Oxford Positron Systems, Westonon-the-Green, United Kingdom; refs. 18, 20, 21) . Before scanning, the mice were treated with either PBS (control) or 5-FU at a single i.p. dose of 165 mg/kg body weight and scanned at 1 to 2 hours after drug injection. For scanning, anesthesia was induced with isofluorane/O 2 /N 2 O and the tail veins of the mice were cannulated. The animals were placed within a thermostatically controlled bed and positioned prone within the scanner. The bed was calibrated to provide a mouse rectal temperature of f37jC.
A bolus injection of [
18 F]FLT (2.96-3.7 MBq; 80-100 ACi) was given i.v. via the tail vein cannula and scanning commenced. Dynamic emission scans were acquired in list-mode format over 60 minutes. The acquired data were then sorted into 0.5-mm sinogram bins and 19 time frames (0.5 Â 0.5 Â 0.5 mm voxels; 4 Â 15, 4 Â 60, and 11 Â 300 seconds) for image reconstruction, which was done by filtered back projection using a two-dimensional Hamming filter (cutoff 0.6). The image data-sets obtained were transferred to a SUN workstation (Ultra 10; SUN Microsystems, Santa Clara, CA) and visualized using the Analyze software (version 6.0; Biomedical Imaging Resource, Mayo Clinic, Rochester, MN). Cumulative images of the dynamic data composed of 0 to 1 minute after injection and 30 to 60 minutes after injection were used for visualization of radiotracer uptake and to define the regions of interest (ROI) on heart (mainly blood pool) and tumors, respectively. ROIs were defined on five tumor and five heart slices (each 0.5 mm thickness). The count densities were averaged for each ROI at each of the 19 time points to obtain a time versus radioactivity curve (TAC) for the ROIs. Tumor TAC was normalized to that of heart at each of the time points to obtain the normalized uptake value (NUV). The [ 18 F]FLT-PET data from heart were used as internal input function for normalizing tumor data because it comprises mainly of blood radioactivity (18) . The NUV at 60 minutes after injection (NUV 60 ), the area under the NUV curve (AUC) calculated as the integral of NUV from 0 to 60 minutes, and the fractional retention of tracer (FRT), the radioactivity at 60 minutes relative to that at 2.5 minutes, were used for comparisons. FRT is a useful variable in that it indicates the proportion of radiotracer delivered to the tumor that is retained. It therefore normalizes tumor [ 18 F]FLT uptake to delivery. Analysis of tumor 2 ¶-deoxyuridine levels. To confirm that thymidylate synthase was inhibited by 5-FU, 2 ¶-deoxyuridine levels were assessed by highperformance liquid chromatography (HPLC). Plasma and RIF-1 tumors were taken from mice treated with PBS or 165 mg/kg 5-FU at 2 hours after injection and immediately snap frozen in liquid nitrogen. This time point was selected to coincide with the imaging assay. Plasma samples (150 AL) were initially prepared using perchlorate protein precipitation; after neutralization and centrifugation, the supernatant was purified by solid-phase extraction. Whole (weighed) tumor samples were homogenized and the homogenate was treated similar to plasma samples. After evaporation to dryness using a vacuum centrifuge, the samples were reconstituted for analysis by reverse-phase HPLC as described previously (22) . 2 ¶-Deoxyuridine was separated on a C18 stationary phase with a mobile phase comprising 0.1% trifluoroacetic acid and detected at 267 nm using a UV photodiode array detector. 2 ¶-Deoxyuridine losses from sample preparation were estimated by measuring the recovered activity of H]2 ¶-deoxyuridine spiked into blank plasma or tumor samples. Chromatographic peak areas for the samples were compared with a calibration curve; data were expressed as micromole per liter and nanomole per gram for plasma and tumors, respectively.
Analysis of tumor TK1 protein and cofactor levels. TK1 protein and cofactor (ATP) were assessed by Western blot and bioluminescence assays, respectively. RIF-1 tumors were excised from mice treated with PBS or 165 mg/kg 5-FU at 2 hours after injection and snap frozen in liquid nitrogen. Tumors were pulverized in liquid nitrogen and homogenized in ice-cold PBS using an Ultra-Turrax homogenizer (IKA, Staufen, Germany). The samples were then centrifuged at 800 Â g ( for 30 minutes at 4jC) and supernatants were analyzed for protein content using a commercial bicinchoninic acid (BCA) protein assay kit (Perbio Science, Cheshire, United Kingdom). Aliquots of the supernatants (containing 30 Ag protein) were mixed with equivalent volumes of native Tris-glycine sample buffer (Invitrogen Life Science, Paisley, United Kingdom) and separated on a precast Tris-glycine (4-20%) gel (Invitrogen). Western blot analysis was done as described previously (18, 20) . For quantification of band intensities, the films were scanned using a GS-710 Calibrated Imaging Densitometer (Bio-Rad Laboratories, Hertfordshire, United Kingdom) and analyzed with the Quantity One software (version 4.0.3; Bio-Rad Laboratories). ATP levels were determined by a bioluminescence assay as described previously (18, 20) using the same supernatants used for the Western blots above. A calibration curve was prepared from ATP standards, which were provided with the ATP assay kit.
Incorporation of radioactivity into DNA. RIF-1 cells were cultured in full growth medium as above and treated with 1 or 10 Ag/mL 5-FU dissolved in PBS or an equal volume of PBS for 2 hours. After drug treatment, the cells were washed and incubated with 0.185 MBq tritiated thymidine (
3 H]FLT for 1 hour. The cells were washed and scraped into plastic tubes. The cellular protein content of whole cells was assayed by a commercial BCA protein assay kit and used for normalization of radioactivity levels in DNA (assuming no losses in the DNA assay) on different days. The cells were centrifuged. DNA was isolated from whole-cell pellet using the AquaPure Genomic Isolation kit (Bio-Rad Laboratories, Hercules, CA). Hydrated DNA samples were placed in opaque 24-well plates (Perkin-Elmer, Beaconsfield, United Kingdom) and left to dry. Aliquots (500 AL) of scintillant (Microscint-40; Perkin-Elmer) were added to each well and the radioactivity in each well was counted on a h-counter (TopCount NXT, Packard Instruments, Meriden, CT). Data were quench corrected and expressed as counts per minute (cpm)/mg protein.
Cellular membrane transport inhibition assays. To determine the mechanism of whole-cell plasma membrane transport, cell uptake studies were done with [ To confirm or rule out the involvement of nucleobase transport, transport studies in PBS-treated cells or 10 Ag/mL 5-FU-treated cells were done as above for [ 18 F]FLT but with 0.185 MBq [ 3 H]adenine as radiotracer. In these studies, 2 mmol/L thymidine was used to saturate phosphorylation of adenine.
Kinetics of nucleoside transport. In these studies, exponentially growing RIF-1 cells were treated for 2 hours with PBS or 5-FU at concentrations of 1 or 10 Ag/mL. Single cells prepared by trypsinization were suspended in HBSS with mild shaking. At the end of the incubation, the reaction was quickly stopped by adding 5 mL ice-cold Na + buffer [150 mmol/L NaCl, 5 mmol/L Tris-HCl (pH 7.4)] and the mixture was centrifuged at 500 Â g for 5 minutes. The supernatant was removed and the cells were washed once and resuspended in 100 AL lysis buffer until they were fully disintegrated. The solution was carefully transferred into opaque 24-well plates and air dried, and the radioactivity was counted (TopCount). Specific binding (binding sites per cell) was defined as the difference in Statistics. Statistical analyses were done using the Prism software, version 4.03 (GraphPad). Differences between PBS-and 5-FU-treated groups were tested for significance using the Student's t test for unpaired data. Two-tailed Ps V0.05 were considered significant.
Results
The accumulation of Figure 1A and B shows the localization of [ 18 F]FLT in RIF-1 tumors 1 to 2 hours after treatment with PBS or 5-FU at the same dose used previously. Localization of radioactivity was seen in the PBS-treated tumor (Fig. 1A ) that was qualitatively enhanced by 5-FU treatment at 1 to 2 hours (Fig. 1B) . Quantitative assessment of the time course of [ 18 F]FLT uptake in RIF-1 tumors after i.v. injection of the radiotracer also showed increased uptake (Fig. 1C) . The two TACs in this case were visually different after f15 minutes. A summary of the kinetic components calculated from the TACs are depicted in Table 1 . All variables, including the NUV 60 , FRT, and AUC, were significantly higher in the 5-FU-treated mice compared with vehicle controls (Table 1) . We also examine whether thymidylate synthase was inhibited under the conditions used. Both plasma and tumor (Fig. 2D) ; the amount of radioactivity in DNA was 0.2% of that in whole cells. This indicates that thymidylate synthase inhibition does not increase [ 18 F]FLT uptake into the DNA pool.
Inhibitor studies indicate a role for equilibrative nucleoside transporter type 1. To examine the role of membrane transport, the uptake of [ (Fig. 3A) . The increased uptake was reduced by pretreatment with equilibrative nucleoside transport (ENT) inhibitors NBTG [type 1 ENT (ENT1) selective] Figure 2 . TK1 protein levels (A) and ATP concentration (B ) in excised PBS-and 5-FU-treated tumors. TK1 protein was analyzed by Western blot and densitometry and expressed as absorbance units (arbitrary); control levels were not significantly different from treated levels; P = 0.89 and 0.40 for the 1-and 2-hour treatment groups, respectively. ATP concentration was analyzed by a bioluminescence method; control levels were not significantly different from treated levels; P = 0.11 and 0.06 for the 1-and 2-hour treatment groups, respectively. DNA content of (Fig. 3B) ; there was a slight decrease with NBTG but that was not statistically significant. This indicates that the decreases in 5-FU-induced [ (Fig. 3C) . The uptake of [ 3 H]TdR in RIF-1 cells was almost completely blocked by NBTG in uninduced and 5-FU-induced cells (Fig. 3C ). Figure 3C also shows that ENT1-dependent transport was lower in magnitude for [ 3 H]NBMPR permits the number of membrane-associated ENT (predominantly ENT1) transporters and affinity of the transporter to be measured (25) (26) (27) . Figure 4 shows the kinetics of Table 2 . There was a 1.5-fold increase in number of transporters on the membrane after treatment of cells with 10 Ag/mL 5-FU for 2 hours, without a change in transporter affinity. A nonsignificant increase in B max was seen at 1 Ag/mL 5-FU; K D was not significantly different from control values in this case too.
Discussion
We have shown for the first time that [ 18 F]FLT-PET can be used to measure thymidylate synthase inhibition in vivo and defined the biochemical mechanism at the cellular level. Thymidylate synthase is a key enzyme for the de novo synthesis of DNA and as such a target for anticancer drug development. Currently the most widely established pharmacodynamic marker used for monitoring the efficacy of thymidylate synthase inhibition is an increase in plasma 2 ¶-deoxyuridine, a consequence of increased intracellular dUMP in proliferating tissues throughout the body (7, 8, 28 (14) . We subsequently showed that this phenomenon occurred in different cell types and following AG337 and 5-FU treatment but not after treatment with cisplatin that does not inhibit thymidylate synthase (24) . In that study, the thymidylate synthase induced increases of [ 3 H]TdR uptake occurred within 1 to 6 hours and classic decreases in [ 3 H]TdR uptake resulting from inhibition of cell proliferation were observed at 24 and 48 hours after treatment (24) . In a recent study by Gibbs et al. (11) , tumor [
125 I]2 ¶-deoxyuridine uptake was shown to increase after treatment of mice with the novel thymidylate synthase inhibitors BGC 638 and BGC 945. Thus, increase in nucleoside uptake after thymidylate synthase inhibition may be a general phenomenon that could be exploited to assess pharmacodynamics of thymidylate synthase inhibitors. Furthermore, it is not cell type dependent as the effects are seen in mouse and human cells, including RIF-1, HT29, and KB cells (11, 24 (29) . Hence, we assessed the feasibility of using this radiotracer for imaging thymidylate synthase inhibition. Marked increase in [
18 F]FLT-PET imaging end points together with marked increases in both plasma and tumor 2 ¶-deoxyuridine were seen 1 to 2 hours after 5-FU treatment in vivo. We have proposed in previous studies that the mechanism of increased radiolabeled thymidine uptake following thymidylate synthase inhibition may involve increased use of the salvage pathway for producing DNA in an attempt of cells to overcome the block in TMP production via the de novo pathway (14, 24) . This assertion was based on the use of radiolabeled thymidine, which is readily incorporated into DNA. In the present study, we showed that [ 3 H]TdR incorporation into DNA was enhanced by 5-FU treatment and that the DNA component comprised a substantial part of wholecell uptake (26.5%). The proportion of [ 3 H]FLT in DNA was only 0.2% that of whole cell and did not change after 5-FU treatment. This finding indicated that the mechanisms of retention of the two radiotracers were different. It also indicated that enhanced incorporation of thymidine analogues into DNA to overcome the block of the de novo pathway per se was not responsible for the general increase in nucleoside uptake. Examination of TK1 and ATP levels, the enzyme system responsible for the initial commitment of thymidine into the salvage pathway, showed no change in levels that could account for the increase in [ 4 These findings indicate that increased salvage kinetics induced by thymidylate synthase inhibition is not due to increased transcription or translation of ENT1 but is largely or exclusively due to redistribution of the transporter from the intracellular compartment of cells to the plasma membrane. ENT1 is predominantly localized on the plasma membrane of both human and mouse cells (32, 33) . In addition to the plasma membrane, ENT1 is known to localize to mitochondria (30) . Whether it is the mitochondrial pool that redistributes to the membrane remains to be determined. It is unlikely that a third ENT family member, ENT3, which is insensitive to NBMPR and has been shown to localize in the intracellular/lysosomal pool (33), will be responsible for the observed effects. Furthermore, the reason why thymidylate synthase inhibitors (11, 14, 24, 34) , but not other anticancer agents, affect radiolabeled nucleoside uptake through ENT1 in this manner remains to be elucidated.
In general, the [ 18 F]FLT-PET changes will depend on the pharmacokinetics of the thymidylate synthase inhibitor, dose, and mechanism of interaction of the inhibitor with thymidylate synthase (i.e., rate and persistence of thymidylate synthase inhibition). A limitation of the technology is the relatively short length of time that PET measurements will continue to show increased [ 18 F]FLT uptake, reflecting inhibition of thymidylate synthase inhibition, rather than a decrease in [ 18 F]FLT uptake, reflecting inhibition of cell proliferation. Our previous studies with 5-FU and AG337 indicate that this time window is z6 and V24 hours in cultured cells (24) . In vivo studies at the same dose of 5-FU used here shows a reduction in [ 18 F]FLT uptake at 24 and 48 hours (18) . Mathematical modeling to calculate [ 18 F]FLT permeability product surface area may allow the thymidylate synthase inhibition effect, which relates to nucleoside transport to be measured at 24 hours or longer. In the use of [
18 F]FLT-PET for monitoring the antiproliferative activity of thymidylate synthase inhibitors, as opposed to its use for determining thymidylate synthase inhibitory activity reported here, the early increases might be interpreted as a ''flare'' effect and confound the [
18 F]FLT-PET studies. We will caution the use of [ 18 F]FLT-PET for monitoring antiproliferative activity of 5-FU-containing regimen during the dosing period (soon after a bolus dose or during and soon after continuous infusion); the same applies to chronic dosing with other thymidylate synthase inhibitors. We will speculate from our previous in vitro and in vivo studies (18, 24) that [ 18 F]FLT-PETbased antiproliferation measurements could be done a few days after 5-FU administration.
Imaging methods could accelerate drug development by providing information on whether adequate levels of drug are achieved, whether the drug hits its intended target, and whether the expected biological activity is achieved (35 
